Carregant...
Miniatura

Tipus de document

Article

Versió

Versió publicada

Data de publicació

Llicència de publicació

cc by (c) Zamora, Víctor et al, 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/222395

Economic Evaluation of Traditional Treatments for Localized Prostate Cancer: A 10‐Year Cohort Study

Títol de la revista

Director/Tutor

ISSN de la revista

Títol del volum

Resum

Objectives: To perform a cost-effectiveness analysis based on primary data from a cohort of patients with localized prostate cancer followed throughout 10 years, comparing radical prostatectomy, brachytherapy, and external beam radiotherapy (EBRT) and applying disease-specific utilities, from a national health system's perspective.Materials and Methods: Patients diagnosed with localized prostate cancer were consecutively recruited in 2003-2005 from 10 Spanish hospitals (n = 674) (ClinicalTrials.gov number: NCT01492751). The expanded prostate cancer index composite (EPIC) and short-form 36 (SF-36) questionnaires were administered through telephone interviews before treatment and annually during follow-up. The outcome measures to evaluate the incremental cost-effectiveness ratio between treatments (ICER) were quality-adjusted life-years (QALYs), calculated by the patient-oriented prostate utility scale (PORPUS) utility index, obtained with a mapping from the EPIC and the SF-36, and survival data. Ten-year medical activities were used to derive costs. Both unweighted and propensity score-weighted analyses were performed.Results: The weighted mean of 10-year QALYs was the highest for radical prostatectomy (8.53), followed by brachytherapy (8.49) and external radiotherapy (8.20), but the difference was only statistically significant with the latter. Costs were significantly higher for brachytherapy (21,348) than radical prostatectomy (12,281) and EBRT (7,560). Compared to EBRT, the weighted ICER for radical prostatectomy was 14,169/QALY gained and 48,417/QALY for brachytherapy.Conclusion: Our findings support that radical prostatectomy was the most cost-effective alternative, but the differences in effectiveness among the three treatments were small. The incremental cost of radical prostatectomy and brachytherapy compared to EBRT, however, does not justify restricting these alternatives.Trial Registration: ClinicalTrials.gov identifier: NCT01492751

Citació

Citació

ZAMORA, Víctor, BOSCH, Guillermo, BECERRA, Virginia, GARIN, Olatz, ÁVILA, Mónica, GUTIÉRREZ, Cristina, FRANCISCO SUÁREZ, José, GOÑI, Alai, MACÍAS, Víctor, MARIÑO, Alfonso, HERVÁS, Asunción, HERRUZO, Ismael, CABRERA, Patricia, PONCE DE LEÓN, Javier, SANCHO, Gemma, PONT, Àngels, RUBIO VALERA, Maria, ALONSO, Jordi, COTS, Francesc, GUEDEA, Ferran, CASTELLS, Manuel, FERRER, Montse, MULTICENTRIC SPANISH GROUP OF CLINICALLY LOCALIZED PROSTATE CANCER, The. Economic Evaluation of Traditional Treatments for Localized Prostate Cancer: A 10‐Year Cohort Study. _European Journal of Cancer Care_. 2025. Vol. 2025, núm. 1. [consulta: 20 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/222395]

Exportar metadades

JSON - METS

Compartir registre